New drug combination delayed disease progression for subgroup of women with metastatic breast cancer
Adding the drug dasatinib to a standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to results of a phase II clinical trial presented at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.Dasatinib is approved by the U.S. Food and Drug Administration for the treatment of chronic myelogenous leukemia. One of the ways it works is by blocking the activity of a protein called Src, which has been recently implicated in the spread of breast cancer to bones.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Breast Cancer Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Clinical Trials | Food and Drug Administration (FDA) | Health | HER2 | Hormones | Leukemia | Women